# A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

> **NCT05392114** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 154 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** Donidalorsen

## Key facts

- **NCT ID:** NCT05392114
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392114, "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05392114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*